KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Current Deferred Revenue: 2015-2022

Historic Current Deferred Revenue for BeOne Medicines (ONC) over the last 5 years, with Dec 2022 value amounting to $213.9 million.

  • BeOne Medicines' Current Deferred Revenue fell 2.67% to $159.0 million in Q2 2023 from the same period last year, while for Jun 2023 it was $159.0 million, marking a year-over-year decrease of 2.67%. This contributed to the annual value of $213.9 million for FY2022, which is 28.71% down from last year.
  • BeOne Medicines' Current Deferred Revenue amounted to $213.9 million in FY2022, which was down 28.71% from $300.0 million recorded in FY2021.
  • In the past 5 years, BeOne Medicines' Current Deferred Revenue ranged from a high of $300.0 million in FY2021 and a low of $18.1 million during FY2018.
  • For the 2-year period, BeOne Medicines' Current Deferred Revenue averaged around $256.9 million, with its median value being $256.9 million (2021).
  • In the last 5 years, BeOne Medicines' Current Deferred Revenue surged by 48.29% in 2018 and then dropped by 28.71% in 2022.
  • Over the past 3 years, BeOne Medicines' Current Deferred Revenue (Yearly) stood at $18.1 million in 2018, then reached $300.0 million in 2021, then fell by 28.71% to $213.9 million in 2022.